Advancing Global Health Equity & Harmonization
Join us for the first annual Cure4Cancer conference focused on advancing global health equity and harmonization.
Stay updated with breaking news from Long Wu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Join us for the first annual Cure4Cancer conference focused on advancing global health equity and harmonization.
Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non-small cell lung cancer, new interim data show, but experts have raised concerns about toxicity.
Osimertinib plus chemotherapy improved PFS by nearly 9 months versus targeted agent alone
Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.
Zorifertinib improves PFS when compared to gefitinib or erlotinib as first-line treatment for EGFR-mutant NSCLC with CNS metastases.